FLNA Stock — Filana Therapeutics, Inc.

Up next

Next earnings call

Nov 4, 2027 Est · unconfirmed · in 66 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Jul 29, 2026

Equibles Rating

blended score · not investment advice

Overall

Strong Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 18.2 · elevated Equity put/call 0.71

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −58%

below

Price vs 50-day avg −29%

below

RSI (14) 24

oversold

MACD trend Negative

52-week position 0%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −27%

trailing

6-month return −55%

trailing

YTD return −56%

this year

Relative strength −63%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

17 of 101 funds reported for Jun 30 · net -82.6K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.91% of float · ▼ -3.9% MoM · 14.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

101 holders — near 3-yr low, contrarian setup

Squeeze score 68

elevated · 0–100

Fundamentals

Fair

Revenue growth +2000%

Y/Y

EPS growth −29%

Y/Y

Free cash flow $-32.8M

Balance sheet $95.5M

net cash

Quant / Vol

risk profile

Very High

Volatility 90%

annualized · 1-yr

Max drawdown −81%

past year

ATR 7.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Jul 29, 2026

second-half 2026

Net cash used in operations Initiated $11M – $15M

year-end 2026

Unrestricted cash at year-end 2026 Initiated $36M – $40M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−58% Bearish

Price vs 50-day avg

−29% Bearish

RSI (14)

24 Neutral

MACD trend

Negative Bearish

52-week position

0% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $1 › 200d $2 — 200d above 50d

Institutional flow Distributing

17 of 101 funds reported for Jun 30 · net -82.6K sh shares · +1 new

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

12.91% of float · ▼ -3.9% MoM · 14.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr low

101 holders — near 3-yr low, contrarian setup

Price context

position in its 52-week range

52-wk low $1 Now $1 · 0% 52-wk high $5

vs 200-day avg -58% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
FLNA Filana Therapeutics, Inc. this stock	$42.75M	-56.1%	+277.6%	—	12.9%
ONC BeOne Medicines Ltd.	$472.90B	+8.8%	+22179.2%	962.4	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$124.46B	+8.2%	+46.2%	29.1	2.0%
REGN Regeneron Pharmaceuticals, Inc.	$72.88B	-9.8%	+20.8%	17.0	3.3%
ARGX Argenx SE	$54.57B	+3.7%	—	—	2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

101

% held: 29.6%
Reported: 17 of 101
Top holder: MARSHALL WACE, LLP

Held Float

View

Held by Funds

Fund positions

29

View

Short & Settlement

Short Interest Falling

Shares short

6.2M

Days to cover: 14.8d
Change: -251.0K sh

View

Short Volume

Short vol %

46%

As of: Jul 29, 2026

Short Total

View

Fails to Deliver

FTD shares

4.4K

Value: $5.4K
As of: Jun 30, 2026

View

Off-Exchange

Off-exchange %

63.4%

Week of: May 4, 2026

Off-exch Lit

View

Financials

Net income (FY)

$-91.0M

EPS diluted: $-1.88

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 11

View

Proposed Sales

Value

$7.6K

Shares: 2.0K
Filed: Dec 2, 2024

View

Earnings & Events

Earnings Calls

Last call

May 7, 2026

View

	5D	20D	120D	MTD	YTD
FLNA	-9.8%	-26.9%	-55.4%	-26.9%	-56.1%
SPY	-1.0%	0.0%	+7.4%	-0.8%	+8.6%
vs SPY	-8.8%	-26.9%	-62.9%	-26.1%	-64.7%

FLNA · Filana Therapeutics, Inc.

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance